Ensysce Biosciences (ENSC) Net Equity Issued and Repurchased (2020 - 2021)
Ensysce Biosciences (ENSC) posted quarterly Net Equity Issued and Repurchased of -$1.2 million for Q3 2021, down 199.42% quarter-over-quarter from -$393379.0 in Q4 2020.
Ensysce Biosciences (ENSC) Net Equity Issued and Repurchased (2020 - 2021) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Net Equity Issued and Repurchased for 2 consecutive years, with -$1.2 million the latest figure, recorded in Q3 2021.
- In Q3 2021, Net Equity Issued and Repurchased changed N/A year-over-year to -$1.2 million; the TTM figure through Dec 2021 stood at -$1.6 million (changed N/A YoY), while the FY2021 annual figure was $6.6 million, up 103.59% from the prior year.
- Net Equity Issued and Repurchased eased to -$1.2 million in Q3 2021 per ENSC's latest filing, from -$393379.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at -$393379.0 in Q4 2020 and bottomed at -$1.2 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -1.18 Mn |
| Sep 30, 2021 | -1.18 Mn |
| Dec 31, 2020 | -393,379.00 |
| Dec 31, 2020 | -393,379.00 |